FOXO Q3: $42,678 Cash, Going Concern Doubt, Grifols Deal Slipping to 2027
Summary
FOXO reported a $101,301 Q3 profit that masks a $2.3M nine-month operating loss, with just $42,678 of cash, $17.9M of debt in default and renewed going-concern doubt. The Grifols acquisition slipped to 2027, and the Ludwig deal hinges on a Nasdaq listing and offering that would first repay $7.8M of senior notes.
Key Events · Earnings and Guidance · FOXO
-
Q3 Profit Is Accounting, Not Operating
Net income attributable to FOXO was $101,301 for Q3 2026 versus a $1.9M loss a year earlier. The nine-month $6.8M profit includes a $9.1M reversal of stock compensation tied to forfeited founder shares, leaving roughly a $2.3M underlying loss.
-
Cash Nearly Gone, Debt All Current
Cash fell to $42,678 at September 30, 2026 from $207,453 at December 31, 2025, against $17.9M of total debt classified as current and a $35.8M working capital deficit.
-
Going Concern Doubt Reaffirmed
Management states substantial doubt about the ability to continue as a going concern, citing defaults on numerous promissory notes accruing $500-per-day penalties and about $3.7M of principal, penalties and interest in arrears.
-
Grifols Deal Slips to 2027, Unfunded
The $3.5M cash purchase of four blood collection centers from Grifols Bio Supplies (plus up to $1.0M earn-out) did not close in Q3 2026. It now needs an FDA license, CLIA certification and a Miami waste permit, and FOXO says it lacks the cash to close.
Analysis · FOXO · Industrial Applications And Services
The $101,301 profit FOXO reported for the third quarter is almost entirely accounting noise. The nine-month $6.8M net income exists only because the company reversed $9.1M of stock compensation after its founder's shares were forfeited. Strip that out and the company lost about $2.3M over nine months while burning through cash. It ended September with $42,678 on hand against $17.9M of debt, all classified current, and a $35.8M working capital deficit. Management repeats that there is substantial doubt about continuing as a going concern, with many notes in default and $500/day penalties accruing. Both growth deals are unfunded and unclosed. The $3.5M Grifols blood-center purchase missed its Q3 target and now needs an FDA license, CLIA certification and cash the company does not have. The Ludwig transaction signed October 25 requires a Nasdaq listing and a public offering within 120 days, and any offering would first have to repay $7.8M of senior notes. A November 8 cyber incident adds operational risk. The equity is levered to financing outcomes, not operations.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FOXO was trading at $0.17 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $279.9K. The 52-week trading range was $0.00 to $7.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.